BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33046620)

  • 1. Breast cancer-induced immune suppression in the sentinel lymph node is effectively countered by CpG-B in conjunction with inhibition of the JAK2/STAT3 pathway.
    van Pul KM; Vuylsteke RJCLM; de Beijer MTA; van de Ven R; van den Tol MP; Stockmann HBAC; de Gruijl TD
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33046620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selectively hampered activation of lymph node-resident dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node.
    van Pul KM; Vuylsteke RJCLM; van de Ven R; Te Velde EA; Rutgers EJT; van den Tol PM; Stockmann HBAC; de Gruijl TD
    J Immunother Cancer; 2019 May; 7(1):133. PubMed ID: 31118093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A
    Koster BD; López González M; van den Hout MF; Turksma AW; Sluijter BJ; Molenkamp BG; van Leeuwen PA; Vosslamber S; Scheper RJ; van den Eertwegh AJ; van den Tol MP; Jordanova EJ; de Gruijl TD
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141(+) Dendritic Cells and Enhanced Cross-Presentation.
    Sluijter BJ; van den Hout MF; Koster BD; van Leeuwen PA; Schneiders FL; van de Ven R; Molenkamp BG; Vosslamber S; Verweij CL; van den Tol MP; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
    Cancer Immunol Res; 2015 May; 3(5):495-505. PubMed ID: 25633713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node.
    van den Hout MF; Sluijter BJ; Santegoets SJ; van Leeuwen PA; van den Tol MP; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
    Cancer Immunol Immunother; 2016 Apr; 65(4):405-15. PubMed ID: 26935057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanoma Sequentially Suppresses Different DC Subsets in the Sentinel Lymph Node, Affecting Disease Spread and Recurrence.
    van den Hout MFCM; Koster BD; Sluijter BJR; Molenkamp BG; van de Ven R; van den Eertwegh AJM; Scheper RJ; van Leeuwen PAM; van den Tol MP; de Gruijl TD
    Cancer Immunol Res; 2017 Nov; 5(11):969-977. PubMed ID: 28935649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.
    Zhao X; Zhang Z; Moreira D; Su YL; Won H; Adamus T; Dong Z; Liang Y; Yin HH; Swiderski P; Pillai RK; Kwak L; Forman S; Kortylewski M
    Mol Ther; 2018 Mar; 26(3):695-707. PubMed ID: 29433938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers.
    Moreira D; Adamus T; Zhao X; Su YL; Zhang Z; White SV; Swiderski P; Lu X; DePinho RA; Pal SK; Kortylewski M
    Clin Cancer Res; 2018 Dec; 24(23):5948-5962. PubMed ID: 30337279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of flowcytometric quantitation of immune effector cell subsets in the sentinel lymph node of the breast after cryopreservation.
    van Pul KM; Vuylsteke RJ; Bril H; Stockmann HB; de Gruijl TD
    J Immunol Methods; 2012 Jan; 375(1-2):189-95. PubMed ID: 22062586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maturation of dendritic cells and T-cell responses in sentinel lymph nodes from patients with breast carcinoma.
    Matsuura K; Yamaguchi Y; Ueno H; Osaki A; Arihiro K; Toge T
    Cancer; 2006 Mar; 106(6):1227-36. PubMed ID: 16475148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy.
    Kortylewski M; Kujawski M; Herrmann A; Yang C; Wang L; Liu Y; Salcedo R; Yu H
    Cancer Res; 2009 Mar; 69(6):2497-505. PubMed ID: 19258507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients.
    Molenkamp BG; van Leeuwen PA; Meijer S; Sluijter BJ; Wijnands PG; Baars A; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
    Clin Cancer Res; 2007 May; 13(10):2961-9. PubMed ID: 17504997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STAT3-silenced human dendritic cells have an enhanced ability to prime IFNγ production by both αβ and γδ T lymphocytes.
    Sanseverino I; Purificato C; Varano B; Conti L; Gessani S; Gauzzi MC
    Immunobiology; 2014 Jul; 219(7):503-11. PubMed ID: 24674241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-mediated inhibition of human dendritic cell differentiation and function is consistently counteracted by combined p38 MAPK and STAT3 inhibition.
    Oosterhoff D; Lougheed S; van de Ven R; Lindenberg J; van Cruijsen H; Hiddingh L; Kroon J; van den Eertwegh AJ; Hangalapura B; Scheper RJ; de Gruijl TD
    Oncoimmunology; 2012 Aug; 1(5):649-658. PubMed ID: 22934257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmacytoid dendritic cells from human lung cancer draining lymph nodes induce Tc1 responses.
    Faith A; Peek E; McDonald J; Urry Z; Richards DF; Tan C; Santis G; Hawrylowicz C
    Am J Respir Cell Mol Biol; 2007 Mar; 36(3):360-7. PubMed ID: 17023687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.
    Zhang Q; Hossain DM; Duttagupta P; Moreira D; Zhao X; Won H; Buettner R; Nechaev S; Majka M; Zhang B; Cai Q; Swiderski P; Kuo YH; Forman S; Marcucci G; Kortylewski M
    Blood; 2016 Mar; 127(13):1687-700. PubMed ID: 26796361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients.
    Molenkamp BG; Sluijter BJ; van Leeuwen PA; Santegoets SJ; Meijer S; Wijnands PG; Haanen JB; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
    Clin Cancer Res; 2008 Jul; 14(14):4532-42. PubMed ID: 18628468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model.
    Molavi O; Ma Z; Hamdy S; Lai R; Lavasanifar A; Samuel J
    Immunol Cell Biol; 2008; 86(6):506-14. PubMed ID: 18392040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut-derived commensal bacterial products inhibit liver dendritic cell maturation by stimulating hepatic interleukin-6/signal transducer and activator of transcription 3 activity.
    Lunz JG; Specht SM; Murase N; Isse K; Demetris AJ
    Hepatology; 2007 Dec; 46(6):1946-59. PubMed ID: 17935227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-specific CD8+ T cell reactivity in the sentinel lymph node of GM-CSF-treated stage I melanoma patients is associated with high myeloid dendritic cell content.
    Vuylsteke RJ; Molenkamp BG; van Leeuwen PA; Meijer S; Wijnands PG; Haanen JB; Scheper RJ; de Gruijl TD
    Clin Cancer Res; 2006 May; 12(9):2826-33. PubMed ID: 16675577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.